Bandaram Pharma Packtech Ltd
Incorporated in 2022, Bandaram Pharma Packtech Ltd deals in procurement and supply of recycled paper[1]
- Market Cap ₹ 50.0 Cr.
- Current Price ₹ 27.8
- High / Low ₹ 49.7 / 22.0
- Stock P/E 128
- Book Value ₹ 7.12
- Dividend Yield 0.36 %
- ROCE 7.67 %
- ROE 7.94 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Stock is trading at 3.90 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of 8.26% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 185 days.
- Promoter holding has decreased over last 3 years: -12.3%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 0.00 | 18.73 | 34.08 | 36.96 | 45.15 | |
| 0.01 | 17.58 | 31.26 | 34.13 | 42.53 | |
| Operating Profit | -0.01 | 1.15 | 2.82 | 2.83 | 2.62 |
| OPM % | 6.14% | 8.27% | 7.66% | 5.80% | |
| 0.00 | 0.19 | 0.03 | 0.09 | 0.10 | |
| Interest | 0.00 | 0.43 | 0.93 | 0.99 | 0.94 |
| Depreciation | 0.00 | 0.59 | 0.73 | 0.61 | 0.94 |
| Profit before tax | -0.01 | 0.32 | 1.19 | 1.32 | 0.84 |
| Tax % | 0.00% | 21.88% | 20.17% | 24.24% | |
| -0.01 | 0.26 | 0.95 | 0.99 | 0.58 | |
| EPS in Rs | -0.01 | 0.12 | 0.79 | 0.82 | 0.27 |
| Dividend Payout % | 0.00% | 21.43% | 12.63% | 12.12% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 366% |
| TTM: | -62% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 1% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 8% |
| Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 7.06 | 3.00 | 12.00 | 12.00 | 12.00 |
| Reserves | -0.06 | 0.08 | 0.28 | 0.65 | 0.80 |
| 0.00 | 14.20 | 12.20 | 17.15 | 21.89 | |
| 0.48 | 2.90 | 7.58 | 9.12 | 5.67 | |
| Total Liabilities | 7.48 | 20.18 | 32.06 | 38.92 | 40.36 |
| 2.87 | 5.03 | 4.48 | 3.95 | 3.69 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 2.09 | 0.00 | 1.40 | 1.40 | 1.40 |
| 2.52 | 15.15 | 26.18 | 33.57 | 35.27 | |
| Total Assets | 7.48 | 20.18 | 32.06 | 38.92 | 40.36 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -1.10 | -4.13 | -4.93 | ||
| -5.30 | -1.58 | -0.08 | ||
| 4.47 | 5.59 | 5.09 | ||
| Net Cash Flow | -1.93 | -0.11 | 0.08 | |
| Free Cash Flow | -3.89 | -4.31 | -5.01 | |
| CFO/OP | -96% | -139% | -163% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 129.01 | 155.51 | 185.27 | |
| Inventory Days | ||||
| Days Payable | ||||
| Cash Conversion Cycle | 129.01 | 155.51 | 185.27 | |
| Working Capital Days | 147.13 | 147.59 | 165.22 | |
| ROCE % | 5.69% | 9.10% | 7.67% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Employees Count ・Standalone data |
|
|||||||||
| Trade Receivables Turnover Ratio Ratio |
||||||||||
| Capital Adequacy Ratio (NBFC Era) % ・Standalone data |
||||||||||
| Inventory Management Contracts (Peak Season Supply) Qualitative (Implicit) ・Standalone data |
||||||||||
| Market Experience in Paper Business Months ・Standalone data |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
30 Apr - Bandaram Pharma Packtech confirms it is not a Large Corporate for FY2025-26; no debt borrowing reported.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Bandaram Pharma Packtech says it is not a large corporate; FY2026-27 initial disclosure not applicable.
-
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
27 Apr - Scrutinizer report for 1st EGM on 27 April 2026; all three resolutions passed.
-
Shareholder Meeting / Postal Ballot-Outcome of EGM
27 Apr - Bandaram Pharma Packtech’s 1st EGM on 27 Apr 2026 passed three resolutions, including an independent director appointment and related-party transactions.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 11 Apr
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2002
from bse
-
Financial Year 2000
from bse
Business Overview:[1]
BPPL is engaged in the business of trading
of paper board and recycled wastepaper